Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.56 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18307658 | 1.00 | LPAR3 (0.56) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18307674 | 1.00 | LPAR3 (0.56) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18307656 | 1.00 | LPAR3 (0.56) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18307669 | 1.00 | LPAR3 (0.56) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18307663 | 1.00 | LPAR3 (0.56) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18307668 | 0.93 | LPAR3 (0.52) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18307672 | 0.93 | LPAR3 (0.52) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL19342540 | 0.93 | LPAR3 (0.52) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18307655 | 0.93 | LPAR3 (0.52) | LPAR3LPAR2LPAR1LPAR5MEN1 | |
| SCHEMBL18307661 | 0.93 | LPAR3 (0.52) | LPAR3LPAR2LPAR1LPAR5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | LPAR3 1414/4885LPAR2 1283/4885LPAR1 1407/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | LPAR3 383/4885LPAR2 433/4885LPAR1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.